← Back to headlines
Oxford's new Ebola vaccine enters first human trial, Serum Institute to produce doses
A new Ebola vaccine developed by Oxford has begun its first human trial, with the Serum Institute of India committed to manufacturing over 620,000 doses.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
